New fine adds to woes for Simcere's vaccines unit
This article was originally published in Scrip
Executive Summary
Simcere Pharmaceutical Group's vaccine subsidiary Jiangsu Yanshen Biological Technology has been fined an additional Yuan4.6 million ($687,000) in relation to the manufacture of a substandard human rabies vaccine in 2008.